Pancreatic Cancer Diagnostic Signature

About Metabolomycs

Founded in 2018, Metabolomycs is a private diagnostics company leveraging advanced mass spectrometry-based metabolomics to develop biochemical signatures for disease detection and prognostication. The company has a strong research foundation, with numerous peer-reviewed publications in oncology and metabolic diseases, and is transitioning this research into a clinical diagnostic test. Its core value proposition is enabling earlier, more personalized interventions by identifying metabolic dysregulations before overt disease manifests.

Therapeutic Areas